Horizon Kinetics’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-24,252
Closed -$441K 487
2018
Q3
$441K Buy
24,252
+2,572
+12% +$45.1K 0.01% 288
2018
Q2
$366K Buy
21,680
+2,408
+12% +$45.5K 0.01% 396
2018
Q1
$378K Buy
19,272
+64
+0.3% +$1.24K 0.01% 400
2017
Q4
$389K Sell
19,208
-4,399
-19% -$80.9K 0.01% 398
2017
Q3
$410K Sell
23,607
-7,022
-23% -$95.1K 0.01% 328
2017
Q2
$393K Buy
30,629
+1
+0% +$13 0.01% 394
2017
Q1
$397K Sell
30,628
-10,538
-26% -$133K 0.01% 414
2016
Q4
$407K Buy
41,166
+8,196
+25% +$89.8K 0.01% 401
2016
Q3
$398K Sell
32,970
-17,270
-34% -$176K 0.01% 417
2016
Q2
$434K Sell
50,240
-5,860
-10% -$57.8K 0.01% 377
2016
Q1
$531K Buy
56,100
+20,992
+60% +$198K 0.01% 305
2015
Q4
$608K Sell
35,108
-5,333
-13% -$85K 0.01% 294
2015
Q3
$543K Sell
40,441
-1,646
-4% -$33K 0.01% 379
2015
Q2
$950K Sell
42,087
-19,302
-31% -$339K 0.01% 248
2015
Q1
$877K Sell
61,389
-29,690
-33% -$428K 0.01% 267
2014
Q4
$879K Buy
91,079
+6,796
+8% +$60.4K 0.01% 276
2014
Q3
$767K Buy
84,283
+7,124
+9% +$67.8K 0.01% 365
2014
Q2
$762K Buy
77,159
+14,509
+23% +$123K 0.01% 375
2014
Q1
$796K Buy
62,650
+27,118
+76% +$403K 0.01% 302
2013
Q4
$533K Buy
35,532
+977
+3% +$12.6K 0.01% 383
2013
Q3
$381K Buy
+34,555
New +$288K 0.01% 344

Other funds holding HALO

Horizon Kinetics's HALO Position: Q4 2018 in Review

Horizon Kinetics sold out of Halozyme (HALO) in Q4 2018, closing a stake of 24,252 shares — an estimated $441K sold.

Horizon Kinetics first reported a position in HALO in Q3 2013 and held it in 21 quarters. The position peaked at $950K in Q2 2015. 195 funds tracked by Wall St. Rank hold HALO as of Q4 2018.

  • Horizon Kinetics reported no remaining Halozyme position as of Q4 2018 after selling out during the quarter.
  • Horizon Kinetics sold 24,252 Halozyme shares in Q4 2018, an estimated $441K.
  • Horizon Kinetics first reported a position in Halozyme in Q3 2013 and held it in 21 quarters.
  • Horizon Kinetics's Halozyme position peaked at $950K in Q2 2015.
  • 195 funds tracked by Wall St. Rank held Halozyme as of Q4 2018.

Based on Horizon Kinetics's 13F filing for Q4 2018, filed 14 Feb 2019.